LNSR trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LNSR achieves its forward estimates and maintains a stable P/E multiple of 1471.8x. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, LENSAR, Inc. (LNSR) has a Wall Street consensus price target of N/A, based on estimates from 3 covering analysts. The company has a market capitalization of $69M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, LNSR trades at a trailing P/E of -2.0x and forward P/E of 1471.8x. Analysts expect EPS to grow -99.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $1.5B | $13.61 | $33.00 | +131.1% | Buy | — | 15 |
ALGNAlign Technology, Inc. | $12.4B | $173.76 | $203.60 | +11.8% | Buy | 16.0x | 33 |
ATRCAtriCure, Inc. | $1.4B | $28.44 | $51.33 | +78.2% | Buy | 768.0x | 19 |
LMATLeMaitre Vascular, Inc. | $2.0B | $88.61 | $127.50 | +35.7% | Buy | 31.3x | 20 |
OMCLOmnicell, Inc. | $1.8B | $38.68 | $57.20 | +46.5% | Hold | 20.2x | 19 |
ABTAbbott Laboratories | $152.6B | $87.78 | $127.46 | +44.2% | Buy | 16.1x | 41 |
BSXBoston Scientific Corporation | $65.9B | $44.33 | $82.90 | +83.0% | Buy | 13.5x | 44 |
SYKStryker Corporation | $116.7B | $304.64 | $387.46 | +25.9% | Buy | 20.5x | 51 |
MDTMedtronic plc | $101.8B | $79.27 | $95.80 | +20.7% | Buy | 13.3x | 51 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
Quick answers to the most common questions about buying LNSR stock.
The consensus price target for LNSR is $N/A, close to the current price of $5.66 (N/A% implied move). Based on 3 analyst estimates, the stock appears fairly valued near current levels.
LNSR has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
At a forward P/E of 1471.7949x, LNSR trades at a premium valuation. The consensus price target of $N/A (N/A% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $N/A for LNSR, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
LNSR is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LNSR stock forecast based on 3 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
LNSR trades at a forward P/E ratio of 1471.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
LNSR appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LNSR analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.